Current prices versus minimum costs of production for CFTR modulators
| Autor: | Jonathan Guo, Junzheng Wang, Jingchun Zhang, Joseph Fortunak, Andrew Hill |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Pulmonary and Respiratory Medicine
Trikafta Cystic Fibrosis Respiratory System Cystic Fibrosis Transmembrane Conductance Regulator 1103 Clinical Sciences Quinolones Aminophenols Drug Combinations Kaftrio Pediatrics Perinatology and Child Health Mutation Humans Elexacaftor/tezacaftor/ivacaftor Benzodioxoles CFTR modulator |
| Popis: | BackgroundWhile the clinical benefits of CFTR modulators are clear, their high prices render them inaccessible outside of a select few countries. Despite this, there is currently limited evidence regarding access to these transformative therapies. Therefore, this study aims to estimate the minimum costs of production of CFTR modulators, assuming robust generic competition, and to compare them with current list prices to evaluate the feasibility of increased global access to treatment.MethodsMinimum costs of production for CFTR modulators were estimated via an algorithm validated in previous literature and identification of cost-limiting key starting materials from published routes of chemical synthesis. This algorithm utilised per kilogram active pharmaceutical ingredient costs obtained from global import/export data. Estimated production costs were compared with published list prices in a range of countries.ResultsCosts of production for tezacaftor/ivacaftor/elexacaftor are estimated at $5676 [$4811-6539] per year, over 90% lower than the US list price. Analysis of chemical structure and published synthetic pathways for tezacaftor/ivacaftor/elexacaftor revealed relatively straightforward routes of synthesis related to currently available products. Total cost of triple therapy for all eligible diagnosed CF patients would be $489 million per year. Comparatively, the annual cost at US list price would be $31.2 billion.ConclusionTezacaftor/ivacaftor/elexacaftor could be produced via generic companies for a fraction of the list price. The current pricing model restricts access to the best available therapy in LMICs, thereby exacerbating existing international inequalities in CF care. Urgent action is needed to increase availability of triple combination treatment worldwide.FundingNone |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|